March 27, 2014 - The "Abstract of the Year" at SIR shows how durable, long-term solutions are possible for the nearly 400,000 people who undergo dialysis every year due to kidney failure and who have few options when a dialysis access site narrows or becomes inaccessible.
Final data from the two-year conclusion of the RENOVA trial (a multicenter randomized comparison of stent graft versus balloon angioplasty) proves a new kind of stent graft is more effective than—and as safe as—balloon angioplasty for treatment of arteriovenous graft stenoses (narrowing of blood vessels). The Society of Interventional Radiology’s (SIR) Annual Scientific Meeting is featuring new research on stent grafts during its scientific sessions at in SIR’s 39th Annual Scientific Meeting, March 22-27, 2014, in San Diego.
Dialysis is very demanding, and anything that prevents access sites from failing and reduces the need for invasive treatments of surgery will dramatically improve patients’ quality of life—while reducing health care costs.
This 28-site prospective controlled U.S. study enrolled 270 patients with malfunctioning upper extremity arteriovenous grafts with stenoses of greater than or equal to 50 percent. Of these, 132 patients received percutaneous transluminal angioplasty or PTA (a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at its end to restore normal blood flow) and 138 received the stent-grafts. At 24-months, the stent graft group’s results remained significantly better with treatment area primary patency at 26.9 percent, more than double that of the PTA-alone group. There was a definitive lower need for repeat intervention and, of those individuals who required reintervention, the time to reintervention was longer in the stent graft group.Back To Top